News

Prim. MUDr. Gustáv Ondrejka: Biological treatment of asthma eliminates the need for systemic corticotherapy

18. 4. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation

Despite advances in the therapy of bronchial asthma, a portion of patients still do not achieve the desired control of the disease. The introduction of biological treatment marked a significant milestone in management, improving the prognosis for patients previously dependent on long-term systemic corticotherapy with all its negative impacts. The recently approved reimbursement for dupilumab expands treatment options for patients with severe asthma, relieving patients of common asthma comorbidities. The current perspective on the treatment of…

Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A

Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the group of factors with an extended half-life. The authors of a systematic review and meta-analysis…

14. 4. 2022 Source: Hemophilia

Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A

Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of the work presented below discuss the significance of prophylactic administration of factor VIII coagulation…

14. 4. 2022 Source: Hemophilia

Brief from ASH 2021: News and Advances in CLL Treatment

The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta in December 2021 brought several new advancements in the treatment of chronic lymphocytic leukemia…

12. 4. 2022 Source: Chronic Lymphocytic Leukemia

Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease

Albuminuria in patients with type 2 diabetes is associated with a higher risk of cardiovascular (CV) events and higher mortality. However, this association has not been thoroughly investigated in…

12. 4. 2022 Source: Diabetes

Bimekizumab –⁠ Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?

In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the first psoriasis treatment that selectively and directly inhibits interleukins IL-17A and IL-17F. It is…

12. 4. 2022 Source: Psoriasis

Benefits of Enoxaparin Prophylaxis in Pregnancy and Postpartum

Study results suggest that the use of low molecular weight heparins during pregnancy could lead to better outcomes for women with thrombophilia and recurrent miscarriages. A group of authors from…

11. 4. 2022 Source: Thromboprophylaxis

Impact of Combined Oral Contraceptives on Body Weight

A relatively recent study investigated changes in the average body weight of women who used combined oral contraceptives with 30 μg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) or 30 μg EE and…

10. 4. 2022 Source: Oral Contraception

Monocyte Distribution Width as an Early Indicator of Sepsis in ICU Patients

Authors of a Franco-Spanish study propose using the monocyte distribution width along with leukocyte count as a screening test to refine the early diagnosis of sepsis in intensive care unit (ICU)…

9. 4. 2022 Source: Because

Curative Potential of Neoadjuvant Denosumab in the Treatment of Giant Cell Spinal Tumor? A Case Study

Portuguese authors present a case study of a young woman diagnosed with a giant cell spinal tumor who achieved complete histological remission following denosumab treatment.

9. 4. 2022 Source: Prevention of Bone Events

Prevention of Skeletal Events in the Therapy of Patients with Advanced Prostate Cancer

Prostate cancer most commonly forms metastases in the bones. In patients with this advanced disease, skeletal events occur, negatively affecting their quality of life. Zoledronic acid and denosumab…

9. 4. 2022 Source: Prevention of Bone Events

The Immune System in the Pathophysiology of ITP

From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.

9. 4. 2022 Source: Immune Thrombocytopenia

Over 10 Years of Experience with TPO-RA in the Treatment of Immune Thrombocytopenia

Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an integral part of the therapy for patients with immune thrombocytopenia (ITP) over the past more than 10 years.…

9. 4. 2022 Source: Immune Thrombocytopenia

Anticoagulation Therapy in Patients on ECMO During the COVID-19 Pandemic

In the past 2 years, the use of extracorporeal membrane oxygenation (ECMO) in intensive care units (ICU) has increased in connection with the treatment of severe COVID-19 pneumonia. Dr. Pilar Marcos…

8. 4. 2022 Source: Life-threatening Bleeding

Can Erdostein Help in Treating Infections Related to Biofilm Formation?

One of the reasons for the very difficult treatment of diseases caused by resistant bacterial strains is the significant ability of these infection-causing agents to form biofilms. What exactly is a…

8. 4. 2022 Source: Cough Therapy

1 … 55 56 57 58 59 … 115

Back Filter by speciality

Remove filters